Abstract
Over the past several years, significant progress has been made in the treatment of gynecologic cancers. However, continued improvements to existing therapies, as well as development of novel approaches to treat these diseases, will be necessary to further reduce mortality. With increasing evidence that ovarian cancer in particular is immunogenic, there is a good reason to investigate the potential of immunotherapies. Recent success in a number of immunotherapy clinical trials targeting other tumor types has laid the groundwork necessary to begin using similar therapies against ovarian and other gynecologic cancers. Here we review past experience and future opportunities for immunotherapy in ovarian cancer, with a focus on vaccines and adoptive T-cell therapy, as well as several nonspecific immunomodulators available for immediate clinical testing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
